Clinical Trial Update: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating larotrectinib for TRK fusion cancers across solid tumors and TRK fusion relapsed acute leukemia in pediatric patients. Results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasms
• Infantile Fibrosarcoma
• Leukemia
• Solid Neoplasms

Drugs mentioned

• Larotrectinib (larotrectinib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Central Nervous System Neoplasm, Infantile Fibrosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-02